{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T12:43:00Z","timestamp":1768567380418,"version":"3.49.0"},"posted":{"date-parts":[[2024,8,13]]},"group-title":"Neurology","reference-count":51,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,8,13]]},"abstract":"Structured Summary<\/jats:title>\n \n Background<\/jats:title>\n \n With increasing recognition of the value of incorporating prognostic markers into amyotrophic lateral sclerosis (ALS) trial design and analysis plans, there is a pressing need to understand\n which<\/jats:italic>\n among the prevailing clinical and biochemical markers have real value, and\n how<\/jats:italic>\n they can be optimally used.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n A subset of patients with ALS recruited through the multi-center Phenotype-Genotype-Biomarker study (clinicaltrials.gov:\n NCT02327845<\/jats:ext-link>\n ) was identified as \u201ctrial-like\u201d based on meeting common trial eligibility criteria. Clinical phenotyping was performed by evaluators trained in relevant assessments. Serum neurofilament light (NfL) and phosphorylated neurofilament heavy (pNfH), urinary p75\n ECD<\/jats:sup>\n , plasma microRNA-181, and an array of biochemical and clinical measures were evaluated for their prognostic value. Associations with functional progression were estimated by random-slopes mixed models of ALS functional rating scale-revised (ALSFRS-R) score. Associations with survival were estimated by log-rank test and Cox proportional hazards regression. Potential sample size savings from adjusting for given biomarkers in a hypothetical trial were estimated.\n <\/jats:p>\n <\/jats:sec>\n \n Findings<\/jats:title>\n \n Baseline serum NfL is a powerful prognostic biomarker, predicting survival and ALSFRS-R rate of decline. Serum NfL <40pg\/ml and >100pg\/ml correspond to future ALSFRS-R slopes of \u223c0.5 and 1.5 points\/month, respectively. Serum NfL also adds value to the best available clinical predictors, encapsulated by the European Network to Cure ALS (ENCALS) predictor score. In models of functional decline, the addition of NfL yields \u223c25% sample size saving above those achieved by inclusion of either clinical predictors or ENCALS score alone. The prognostic value of serum pNfH, urinary p75\n ECD<\/jats:sup>\n , and plasma miR-181ab is more limited.\n <\/jats:p>\n <\/jats:sec>\n \n Interpretation<\/jats:title>\n Among the multitude of biomarkers considered, only blood NfL adds value to the ENCALS prediction model and should be incorporated into analysis plans for all ongoing and future ALS trials. Defined thresholds of NfL might also be used in trial design, for enrichment or stratified randomisation, to improve trial efficiency.<\/jats:p>\n <\/jats:sec>\n \n Funding<\/jats:title>\n NIH (U01-NS107027, U54-NS092091). ALSA (16-TACL-242).<\/jats:p>\n <\/jats:sec>\n \n Research in Context<\/jats:title>\n \n Evidence Before This Study<\/jats:title>\n The phenotypic heterogeneity of ALS poses a challenge for clinical trials, making it more difficult to discern therapeutic effects of investigational agents amidst the noise of natural variability. Prognostic markers are important tools to help mitigate this issue. A host of clinical markers and putative biomarkers have been proposed to have prognostic value, but their relative utility, especially when considered jointly, and the practical implications of their use, have not been well defined.<\/jats:p>\n <\/jats:sec>\n \n Added Value of This Study<\/jats:title>\n \n Using a trial-like population from a natural history study, in which clinical trial-grade phenotypic data and multi-modal biomarker data were collected, we show that a subset of clinical factors, encapsulated by the ENCALS predictive model score, and serum neurofilament light chain (NfL) are the most powerful prognostic markers when considering either ALSFRS-R functional decline or permanent assisted ventilation (PAV)\/tracheostomy-free survival. Importantly, serum NfL adds prognostic value even after adjusting for the ENCALS score, yielding an additional sample size saving of \u223c27% in a hypothetical future clinical trial. While serum phosphorylated neurofilament heavy chain (pNfH), urinary p75\n ECD<\/jats:sup>\n , and plasma miR-181ab each holds some prognostic value, when considered together with the ENCALS score and serum NfL, only p75\n ECD<\/jats:sup>\n may yield additional but modest sample size saving.\n <\/jats:p>\n <\/jats:sec>\n \n Implication of All Available Evidence<\/jats:title>\n \n Blood NfL is a validated biomarker for multiple contexts-of-use. As a prognostic marker, it should be used together with clinical predictors, such as the ENCALS predictive model score, in all ongoing and future ALS clinical trials. The utility of urinary p75\n ECD<\/jats:sup>\n and plasma miR-181ab is less clear. Serum pNfH, as well as serum uric acid, albumin, creatinine, and C-reactive protein (CRP), provide no additional prognostic information.\n <\/jats:p>\n <\/jats:sec>\n <\/jats:sec>","DOI":"10.1101\/2024.08.12.24311876","type":"posted-content","created":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T13:55:21Z","timestamp":1723557321000},"source":"Crossref","is-referenced-by-count":1,"title":["Prognostic Clinical and Biological Markers for Amyotrophic Lateral Sclerosis Disease Progression: Validation and Implications for Clinical Trial Design and Analysis"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4241-5135","authenticated-orcid":false,"given":"Michael","family":"Benatar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric A","family":"Macklin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Malaspina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary-Louise","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eran","family":"Hornstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittoria","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"Renfrey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Shepheard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iddo","family":"Magen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yahel","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volkan","family":"Granit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey M","family":"Statland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeannine M","family":"Heckmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Rademakers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline A","family":"McHutchison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard","family":"Petrucelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corey T","family":"McMillan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne","family":"Wuu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2024081602350563000_2024.08.12.24311876v1.1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.24979"},{"issue":"1","key":"2024081602350563000_2024.08.12.24311876v1.2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40035-021-00257-y","article-title":"Neurofilament light and heterogeneity of disease progression in amyotrophic lateral sclerosis: development and validation of a prediction model to improve interventional trials","volume":"10","year":"2021","journal-title":"Transl Neurodegener"},{"key":"2024081602350563000_2024.08.12.24311876v1.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30089-9"},{"issue":"1","key":"2024081602350563000_2024.08.12.24311876v1.4","first-page":"e59","article-title":"Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS","volume":"95","year":"2020","journal-title":"Neurology"},{"key":"2024081602350563000_2024.08.12.24311876v1.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204705"},{"key":"2024081602350563000_2024.08.12.24311876v1.6","doi-asserted-by":"crossref","unstructured":"Benatar M , Wuu J , Turner MR . Neurofilament light chain in drug development for amyotrophic lateral sclerosis: a critical appraisal. Brain: a journal of neurology 2022.","DOI":"10.1093\/brain\/awac394"},{"issue":"7","key":"2024081602350563000_2024.08.12.24311876v1.7","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/acn3.51078","article-title":"Longitudinal biomarkers in amyotrophic lateral sclerosis","volume":"7","year":"2020","journal-title":"Annals of clinical and translational neurology"},{"issue":"1","key":"2024081602350563000_2024.08.12.24311876v1.8","doi-asserted-by":"crossref","first-page":"fcac029","DOI":"10.1093\/braincomms\/fcac029","article-title":"Multicentre appraisal of amyotrophic lateral sclerosis biofluid biomarkers shows primacy of blood neurofilament light chain","volume":"4","year":"2022","journal-title":"Brain Commun"},{"key":"2024081602350563000_2024.08.12.24311876v1.9","doi-asserted-by":"crossref","unstructured":"Boylan KB , Glass JD , Crook JE , et al. Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2012.","DOI":"10.1136\/jnnp-2012-303768"},{"key":"2024081602350563000_2024.08.12.24311876v1.10","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003741"},{"key":"2024081602350563000_2024.08.12.24311876v1.11","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-021-00936-z"},{"key":"2024081602350563000_2024.08.12.24311876v1.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2009.06.002"},{"issue":"12","key":"2024081602350563000_2024.08.12.24311876v1.13","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.2169\/internalmedicine.51.7465","article-title":"Relationships between disease progression and serum levels of lipid, urate, creatinine and ferritin in Japanese patients with amyotrophic lateral sclerosis: a cross-sectional study","volume":"51","year":"2012","journal-title":"Intern Med"},{"issue":"9","key":"2024081602350563000_2024.08.12.24311876v1.14","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00415-012-6440-7","article-title":"Uric acid levels predict survival in men with amyotrophic lateral sclerosis","volume":"259","year":"2012","journal-title":"Journal of neurology"},{"issue":"3","key":"2024081602350563000_2024.08.12.24311876v1.15","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s11011-014-9510-y","article-title":"Serum uric acid level is associated with the prevalence but not with survival of amyotrophic lateral sclerosis in a Chinese population","volume":"29","year":"2014","journal-title":"Metab Brain Dis"},{"issue":"9","key":"2024081602350563000_2024.08.12.24311876v1.16","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1001\/jamaneurol.2014.1129","article-title":"Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study","volume":"71","year":"2014","journal-title":"JAMA neurology"},{"key":"2024081602350563000_2024.08.12.24311876v1.17","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-017-3138-8"},{"issue":"1-2","key":"2024081602350563000_2024.08.12.24311876v1.18","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/21678421.2016.1214733","article-title":"Serum urate at trial entry and ALS progression in EMPOWER","volume":"18","year":"2017","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"3","key":"2024081602350563000_2024.08.12.24311876v1.19","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/mus.25950","article-title":"Urate levels predict survival in amyotrophic lateral sclerosis: Analysis of the expanded Pooled Resource Open-Access ALS clinical trials database","volume":"57","year":"2018","journal-title":"Muscle & nerve"},{"key":"2024081602350563000_2024.08.12.24311876v1.20","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3051"},{"key":"2024081602350563000_2024.08.12.24311876v1.21","doi-asserted-by":"publisher","DOI":"10.1080\/14660820510027035"},{"issue":"6","key":"2024081602350563000_2024.08.12.24311876v1.22","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1001\/jamaneurol.2016.6179","article-title":"Serum C-Reactive Protein as a Prognostic Biomarker in Amyotrophic Lateral Sclerosis","volume":"74","year":"2017","journal-title":"JAMA neurology"},{"issue":"1","key":"2024081602350563000_2024.08.12.24311876v1.23","doi-asserted-by":"crossref","first-page":"4374","DOI":"10.1038\/s41598-017-04706-5","article-title":"Adipokines, C-reactive protein and Amyotrophic Lateral Sclerosis - results from a population-based ALS registry in Germany","volume":"7","year":"2017","journal-title":"Sci Rep"},{"key":"2024081602350563000_2024.08.12.24311876v1.24","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(99)00210-5"},{"key":"2024081602350563000_2024.08.12.24311876v1.25","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000194316.91908.8a"},{"issue":"7-8","key":"2024081602350563000_2024.08.12.24311876v1.26","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1080\/21678421.2022.2039713","article-title":"Defining cognitive impairment in amyotrophic lateral sclerosis: an evaluation of empirical approaches","volume":"23","year":"2022","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"2024081602350563000_2024.08.12.24311876v1.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneumeth.2006.05.022"},{"key":"2024081602350563000_2024.08.12.24311876v1.28","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/92.4.415"},{"issue":"4","key":"2024081602350563000_2024.08.12.24311876v1.29","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/ene.15237","article-title":"Urinary neopterin: A novel biomarker of disease progression in amyotrophic lateral sclerosis","volume":"29","year":"2022","journal-title":"Eur J Neurol"},{"issue":"6","key":"2024081602350563000_2024.08.12.24311876v1.30","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/BF00377856","article-title":"WHO global project on biological monitoring of chemical exposure at the workplace","volume":"68","year":"1996","journal-title":"Int Arch Occup Environ Health"},{"key":"2024081602350563000_2024.08.12.24311876v1.31","doi-asserted-by":"crossref","unstructured":"DeJesus-Hernandez M , Mackenzie IR , Boeve BF , et al. Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS. Neuron 2011.","DOI":"10.1016\/j.neuron.2011.09.011"},{"issue":"3-4","key":"2024081602350563000_2024.08.12.24311876v1.32","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/21678421.2016.1267768","article-title":"Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria","volume":"18","year":"2017","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"2024081602350563000_2024.08.12.24311876v1.33","doi-asserted-by":"crossref","unstructured":"McHutchison CA , Wuu J , McMillan CT , et al. Temporal course of cognitive and behavioural changes in motor neuron diseases. J Neurol Neurosurg Psychiatry 2023.","DOI":"10.1136\/jnnp-2023-331697"},{"key":"2024081602350563000_2024.08.12.24311876v1.34","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-199507000-00005"},{"key":"2024081602350563000_2024.08.12.24311876v1.35","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2021-327129"},{"key":"2024081602350563000_2024.08.12.24311876v1.36","doi-asserted-by":"publisher","DOI":"10.1111\/ane.13698"},{"issue":"6","key":"2024081602350563000_2024.08.12.24311876v1.37","doi-asserted-by":"crossref","first-page":"fcad287","DOI":"10.1093\/braincomms\/fcad287","article-title":"Urinary biomarkers for amyotrophic lateral sclerosis: candidates, opportunities and considerations","volume":"5","year":"2023","journal-title":"Brain Commun"},{"key":"2024081602350563000_2024.08.12.24311876v1.38","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70222-4"},{"key":"2024081602350563000_2024.08.12.24311876v1.39","doi-asserted-by":"crossref","unstructured":"Vucic S , Menon P , Huynh W , et al. Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label extension. EClinicalMedicine 2023; 60: 102036.","DOI":"10.1016\/j.eclinm.2023.102036"},{"issue":"5","key":"2024081602350563000_2024.08.12.24311876v1.40","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1177\/1740774519858914","article-title":"Design and analysis of a clinical trial using previous trials as historical control","volume":"16","year":"2019","journal-title":"Clin Trials"},{"issue":"3-4","key":"2024081602350563000_2024.08.12.24311876v1.41","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1080\/21678421.2021.1879865","article-title":"An old friend who has overstayed their welcome: the ALSFRS-R total score as primary endpoint for ALS clinical trials","volume":"22","year":"2021","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"2024081602350563000_2024.08.12.24311876v1.42","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-022-01271-2"},{"key":"2024081602350563000_2024.08.12.24311876v1.43","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2016-314661"},{"key":"2024081602350563000_2024.08.12.24311876v1.44","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-010-5609-1"},{"issue":"5-6","key":"2024081602350563000_2024.08.12.24311876v1.45","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3109\/21678421.2016.1140786","article-title":"The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onset","volume":"17","year":"2016","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"3-4","key":"2024081602350563000_2024.08.12.24311876v1.46","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1080\/21678421.2024.2320880","article-title":"The ALSFRS-R Summit: a global call to action on the use of the ALSFRS-R in ALS clinical trials","volume":"25","year":"2024","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"2024081602350563000_2024.08.12.24311876v1.47","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001642"},{"issue":"1-2","key":"2024081602350563000_2024.08.12.24311876v1.48","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1080\/21678421.2016.1241279","article-title":"Diagnostic and prognostic significance of neurofilament light chain NF-L, but not progranulin and S100B, in the course of amyotrophic lateral sclerosis: Data from the German MND-net","volume":"18","year":"2017","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"2024081602350563000_2024.08.12.24311876v1.49","doi-asserted-by":"publisher","DOI":"10.1111\/nan.12511"},{"key":"2024081602350563000_2024.08.12.24311876v1.50","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-318704"},{"key":"2024081602350563000_2024.08.12.24311876v1.51","doi-asserted-by":"publisher","DOI":"10.1002\/ANA.26860"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2024.08.12.24311876","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:09:14Z","timestamp":1768507754000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2024.08.12.24311876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,13]]},"references-count":51,"URL":"https:\/\/doi.org\/10.1101\/2024.08.12.24311876","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1016\/j.ebiom.2024.105323","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2024,8,13]]},"subtype":"preprint"}}